Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

TSBX

Turnstone Biologics Corp

May 01 • 04:00PM ET

2.60

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI VXF IWN IWO VTWO IWC VTWG VTWV URTY

Index	RUT	P/E	-	EPS (ttm)	-2.41	Insider Own	42.82%	Shs Outstand	23.10M	Perf Week	-15.31%
Market Cap	60.14M	Forward P/E	-	EPS next Y	-3.22	Insider Trans	0.00%	Shs Float	13.23M	Perf Month	-10.65%
Income	-55.61M	PEG	-	EPS next Q	-0.78	Inst Own	34.10%	Short Float	4.76%	Perf Quarter	-1.14%
Sales	19.31M	P/S	3.11	EPS this Y	30.20%	Inst Trans	-	Short Ratio	3.64	Perf Half Y	5.26%
Book/sh	4.27	P/B	0.61	EPS next Y	3.50%	ROA	-	Short Interest	0.63M	Perf Year	-
Cash/sh	4.10	P/C	0.63	EPS next 5Y	21.20%	ROE	-	52W Range	1.62 - 13.20	Perf YTD	2.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-55.69%	52W High	-80.30%	Beta	-
Dividend TTM	-	Quick Ratio	8.57	Sales past 5Y	-50.65%	Gross Margin	85.50%	52W Low	60.00%	ATR (14)	0.36
Dividend Ex-Date	-	Current Ratio	8.57	EPS Y/Y TTM	-	Oper. Margin	-305.77%	RSI (14)	41.97	Volatility	9.84% 12.76%
Employees	80	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-288.05%	Recom	1.67	Target Price	13.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-4.19%	Payout	-	Rel Volume	0.33	Prev Close	2.60
Sales Surprise	-	EPS Surprise	15.44%	Sales Q/Q	-100.00%	Earnings	Mar 21 AMC	Avg Volume	173.01K	Price	2.60
SMA20	-13.17%	SMA50	-19.53%	SMA200	-40.07%	Trades		Volume	56,896	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-16-23	Initiated	SVB Securities	Market Perform
Aug-15-23	Initiated	Piper Sandler	Overweight	$20
Aug-15-23	Initiated	BofA Securities	Buy	$18

Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Mar-22-24 07:52AM	TSBX Stock Earnings: Turnstone Biologics Beats EPS for Q4 2023 (InvestorPlace) -10.48%
Mar-21-24 05:06PM	Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire) +8.44%
Feb-21-24 06:00AM	Turnstone Biologics to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.49%
Feb-20-24 05:00PM	Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq. (GlobeNewswire) -11.67%
06:00AM	Loading…
Nov-27-23 06:00AM	Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-09-23 09:49PM	Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -11.94%
Nov-03-23 06:00AM	Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Oct-30-23 06:00AM	Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber (GlobeNewswire) +24.12%
Sep-28-23 06:00AM	Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire) +10.36%
Sep-01-23 05:57PM	Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +10.47%
Aug-14-23 08:41PM	Steven Cohen's Q2 2023 13F Filing Update: Top Trades and Portfolio Overview (GuruFocus.com)
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com) -5.67%
Jul-27-23 07:01PM	Steven Cohen Acquires Stake in Turnstone Biologics Corp (GuruFocus.com)
05:36PM	FMR LLC Acquires Significant Stake in Turnstone Biologics Corp (GuruFocus.com)
02:15AM	Loading…
Jul-21-23 02:15AM	Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Turnstone Biologics Corp. operates as a clinical stage biotechnology company. It engages in the business of developing and commercializing therapeutics. The company is focused on developing new medicines to treat and cure patients with solid tumors. Turnstone Biologics was founded in 2015 and is headquartered in La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jerel Davis	Director	Jul 25 '23	Buy	12.00	225,000	2,700,000	2,726,322	Jul 27 04:21 PM
Versant Ventures V, LLC	10% Owner	Jul 25 '23	Buy	12.00	225,000	2,700,000	2,726,322	Jul 27 04:23 PM
ORBIMED ADVISORS LLC	Director	Jul 20 '23	Buy	12.00	416,666	4,999,992	3,099,265	Jul 24 04:38 PM
Gupta Rishi	Director	Jul 20 '23	Buy	12.00	416,666	4,999,992	3,099,265	Jul 24 04:40 PM

Open in Screener

RPTX

Repare Therapeutics Inc

May 01 • 04:00PM ET

3.30

Dollar change +0.20
Percentage change 6.45	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

RPTX Repare Therapeutics Inc daily Stock Chart

Held by: ARKG VHT CNCR AVSC INNO DFAS AVUS GWX

Index	-	P/E	-	EPS (ttm)	-2.23	Insider Own	32.40%	Shs Outstand	42.18M	Perf Week	0.00%
Market Cap	139.19M	Forward P/E	-	EPS next Y	-3.20	Insider Trans	17.04%	Shs Float	28.52M	Perf Month	-24.14%
Income	-93.80M	PEG	-	EPS next Q	0.02	Inst Own	56.04%	Short Float	2.13%	Perf Quarter	-49.54%
Sales	51.13M	P/S	2.72	EPS this Y	-18.96%	Inst Trans	-4.82%	Short Ratio	4.78	Perf Half Y	2.48%
Book/sh	5.03	P/B	0.66	EPS next Y	-20.69%	ROA	-30.36%	Short Interest	0.61M	Perf Year	-64.17%
Cash/sh	5.30	P/C	0.62	EPS next 5Y	-	ROE	-38.16%	52W Range	2.98 - 13.85	Perf YTD	-54.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-41.74%	ROI	-44.02%	52W High	-76.17%	Beta	0.68
Dividend TTM	-	Quick Ratio	6.24	Sales past 5Y	1420.60%	Gross Margin	92.98%	52W Low	10.74%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	6.24	EPS Y/Y TTM	-221.34%	Oper. Margin	-224.43%	RSI (14)	34.83	Volatility	6.42% 7.65%
Employees	179	Debt/Eq	0.02	Sales Y/Y TTM	-61.21%	Profit Margin	-183.44%	Recom	1.43	Target Price	15.33
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	11.67%	Payout	-	Rel Volume	1.60	Prev Close	3.10
Sales Surprise	-31.33%	EPS Surprise	-86.84%	Sales Q/Q	-28.31%	Earnings	Feb 28 BMO	Avg Volume	127.36K	Price	3.30
SMA20	-6.01%	SMA50	-31.37%	SMA200	-52.04%	Trades		Volume	203,900	Change	6.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-23	Upgrade	Stifel	Hold → Buy	$11 → $16
Feb-03-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $15
Jan-06-23	Initiated	CapitalOne	Overweight	$28
Apr-12-22	Downgrade	Stifel	Buy → Hold	$11
Mar-17-22	Resumed	Goldman	Buy	$43
Sep-23-21	Initiated	Stifel	Buy	$48
Sep-13-21	Initiated	H.C. Wainwright	Buy	$54
Jun-28-21	Initiated	Guggenheim	Buy	$46
Mar-01-21	Initiated	Berenberg	Buy	$51
Oct-28-20	Initiated	Northland Capital	Outperform	$38
Jul-14-20	Initiated	Piper Sandler	Overweight
Jul-14-20	Initiated	Morgan Stanley	Overweight	$37
Jul-14-20	Initiated	Goldman	Neutral	$27
Jul-14-20	Initiated	Cowen	Outperform

Show Previous Ratings

Apr-30-24 07:05AM	Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition (Business Wire)
07:05AM	Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition (Business Wire)
Apr-26-24 04:05PM	Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors (Business Wire)
Feb-29-24 07:05AM	Repare Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire) +5.30%
Feb-28-24 07:36AM	Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023 (GuruFocus.com)
07:05AM	Loading…
07:05AM	Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 10:00AM	Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks) -5.28%
Feb-15-24 07:05AM	Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664 (Business Wire)
Feb-13-24 04:45AM	Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock? (Zacks) -15.58%
Feb-12-24 04:05PM	Repare Therapeutics to Regain Global Rights to Camonsertib (Business Wire) +8.80%
Jan-25-24 07:00AM	Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment (Business Wire) +6.95%
Jan-08-24 07:00AM	Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones (Business Wire) +8.32%
Jan-04-24 04:05PM	Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer (Business Wire)
Dec-29-23 04:05PM	Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans (Business Wire)
Nov-20-23 08:19AM	Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why (Zacks)
07:00AM	Loading…
Nov-15-23 07:00AM	Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Pol Inhibitor (Business Wire) +29.66%
Nov-09-23 11:38AM	These Biotech Stocks Could Double Your Money, According To Analysts (Benzinga) -10.83%
08:16AM	Repare Therapeutics Inc (RPTX) Reports Q3 2023 Financial Results Amid Pipeline Progress (GuruFocus.com)
07:00AM	Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-07-23 07:00AM	Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast (Business Wire)
Nov-06-23 11:35AM	Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Ken Griffin, Guardian Capital LP, Two Sigma, Repare Therapeutics Inc. (RPTX), Remitly Global Inc (RELY), and More (Insider Monkey) +14.70%
07:00AM	Repare Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire)
Oct-13-23 09:40AM	Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib (Business Wire) -5.71%
Oct-11-23 09:35AM	Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround (Zacks) -7.40%
Oct-09-23 09:35AM	Here's Why Repare Therapeutics Inc. (RPTX) is Poised for a Turnaround After Losing -26.14% in 4 Weeks (Zacks)
Oct-03-23 07:00AM	Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Business Wire)
Sep-20-23 04:26AM	Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength? (Zacks)
Sep-19-23 07:00AM	Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Business Wire) +12.23%
Sep-06-23 07:00AM	Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey)
02:54PM	Loading…
Aug-16-23 02:54PM	Wall Street Thinks This Cathie Wood Stock Could Jump by 187% (Motley Fool)
Aug-09-23 05:40PM	Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-05-23 03:30PM	10 Oversold Canadian Stocks To Buy (Insider Monkey)
Jul-16-23 10:36AM	Repare Therapeutics (NASDAQ:RPTX) shareholders have endured a 52% loss from investing in the stock three years ago (Simply Wall St.)
Jun-08-23 09:49AM	Repare Therapeutics Releases Early Anticancer Activity From Its Monotherapy, Combination Trials (Benzinga)
07:00AM	Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-07-23 04:05PM	Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials (Business Wire)
Jun-06-23 07:00AM	Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors (Business Wire)
Jun-05-23 06:36AM	Repare Therapeutics Inc.'s (NASDAQ:RPTX) market cap touched US$481m last week, benefiting both private equity firms who own 34% as well as institutions (Simply Wall St.)
Jun-02-23 07:00AM	Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights (Business Wire) +7.43%
May-22-23 07:00AM	Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-14-23 08:04AM	Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31% (Simply Wall St.)
May-12-23 06:19AM	Earnings Update: Repare Therapeutics Inc. (NASDAQ:RPTX) Just Reported And Analysts Are Boosting Their Estimates (Simply Wall St.)
May-11-23 06:13AM	A Look At The Intrinsic Value Of Repare Therapeutics Inc. (NASDAQ:RPTX) (Simply Wall St.)
May-09-23 06:55PM	Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results (Business Wire)
May-03-23 09:55AM	How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 214.72% (Zacks)
Apr-28-23 04:05PM	Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors (Business Wire)
Apr-18-23 02:32PM	Repare Therapeutics Inc.'s (NASDAQ:RPTX) Share Price Is Matching Sentiment Around Its Revenues (Simply Wall St.)
10:15AM	Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting (Business Wire)
Mar-29-23 07:25AM	We're Interested To See How Repare Therapeutics (NASDAQ:RPTX) Uses Its Cash Hoard To Grow (Simply Wall St.)
Mar-14-23 04:58PM	Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306 (Business Wire)
Mar-02-23 05:39AM	Repare Therapeutics Full Year 2022 Earnings: US$0.69 loss per share (vs US$2.83 loss in FY 2021) (Simply Wall St.)
Feb-28-23 08:15PM	Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-06-23 05:18AM	Shareholders in Repare Therapeutics (NASDAQ:RPTX) are in the red if they invested a year ago (Simply Wall St.)
Feb-02-23 07:00AM	Repare Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire)
Jan-24-23 04:33AM	Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength? (Zacks)
Jan-20-23 09:55AM	Repare Therapeutics Inc. (RPTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-19-23 07:00AM	Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals (Business Wire)
Dec-27-22 05:34AM	Hedge funds own 26% of Repare Therapeutics Inc. (NASDAQ:RPTX) shares but private equity firms control 36% of the company (Simply Wall St.)
Dec-19-22 07:00AM	Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans (Business Wire)
Dec-02-22 10:54AM	Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data (Zacks) +6.85%
09:35AM	Repare Therapeutics Inc. (RPTX) Just Overtook the 20-Day Moving Average (Zacks)
Dec-01-22 09:55AM	How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 95% (Zacks)
Nov-16-22 05:35AM	Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 15% (Simply Wall St.)
Nov-14-22 09:55AM	Can Repare Therapeutics Inc. (RPTX) Climb 106% to Reach the Level Wall Street Analysts Expect? (Zacks) +7.08%
Nov-09-22 05:35PM	Repare Therapeutics Inc. (RPTX) Q3 Earnings and Revenues Surpass Estimates (Zacks)
04:05PM	Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results (Business Wire)
Nov-07-22 07:00AM	Repare Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire)
Oct-13-22 11:08AM	BeiGene, Ltd. (BGNE) Soars 20.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-12-22 09:10AM	Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth (Simply Wall St.)
Sep-07-22 07:17AM	A Repare Therapeutics Inc. (NASDAQ:RPTX) insider increased their holdings last year (Simply Wall St.) +5.17%
07:00AM	Repare Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire)
Aug-11-22 06:55AM	Repare Therapeutics (NASDAQ:RPTX) investors are sitting on a loss of 63% if they invested a year ago (Simply Wall St.)
Aug-04-22 06:35PM	Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +5.04%
04:05PM	Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results (Business Wire)
Jun-30-22 01:08PM	Biotech ETF Tops in June: 5 Stocks That Outperform (Zacks)
Jun-07-22 07:00AM	Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference (Business Wire)
Jun-02-22 03:26PM	Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug (Zacks) +44.80%
12:30PM	Why Repare Therapeutics Stock Is Skyrocketing Today (Motley Fool)
11:01AM	Roche Shows Interest in This Small-Cap Biotech. Should You? (TheStreet.com)
08:00AM	Roche, Repare's licensing deal includes milestone payments worth up to $1.2 billion (MarketWatch)
Jun-01-22 06:03PM	Repare Therapeutics shares rise 18% after news of Roche deal (MarketWatch)
04:05PM	Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500) (Business Wire)
May-09-22 07:00AM	Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day (Business Wire) -8.62%
May-05-22 08:35PM	Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.79%
04:05PM	Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results (Business Wire)
09:04AM	Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth (Simply Wall St.)
May-04-22 05:25PM	Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-20-22 11:00AM	Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification (Business Wire)
Apr-13-22 08:24AM	Repare Therapeutics Inc. (RPTX) Stock Jumps 9.1%: Will It Continue to Soar? (Zacks) +8.13%
Apr-12-22 09:32AM	Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors (Benzinga) +9.06%
Apr-11-22 04:05PM	Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting (Business Wire) -7.74%
Apr-08-22 01:00PM	Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting (Business Wire) -18.67%
Mar-30-22 10:17AM	Goldman Sachs Bullish on These 2 Stocks for 80% Upside (Or More) (TipRanks)
Mar-08-22 04:30PM	Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting (Business Wire)
Mar-07-22 12:07PM	Repare Therapeutics Highlights Early RP-3500 Data In Solid Tumor Patients (Benzinga)
07:00AM	Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress (Business Wire)

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Segal Lloyd Mitchell	PRESIDENT AND CEO	Apr 01 '24	Sale	4.63	2,491	11,533	107,558	Apr 01 09:31 PM
Forte Steve	EVP, CHIEF FINANCIAL OFFICER	Apr 01 '24	Sale	4.61	789	3,637	44,775	Apr 01 09:30 PM
Zinda Michael	EVP, CHIEF SCIENTIFIC OFFICER	Apr 01 '24	Sale	4.66	410	1,911	71,908	Apr 01 09:28 PM
Koehler Maria	EVP, CHIEF MEDICAL OFFICER	Apr 01 '24	Sale	4.66	300	1,398	231,409	Apr 01 09:27 PM
Segal Lloyd Mitchell	PRESIDENT AND CEO	Mar 28 '24	Sale	4.62	2,650	12,243	110,049	Apr 01 09:31 PM
Forte Steve	EVP, CHIEF FINANCIAL OFFICER	Mar 28 '24	Sale	4.62	825	3,812	45,564	Apr 01 09:30 PM
Koehler Maria	EVP, CHIEF MEDICAL OFFICER	Mar 28 '24	Sale	4.64	500	2,320	231,709	Apr 01 09:27 PM
Zinda Michael	EVP, CHIEF SCIENTIFIC OFFICER	Mar 28 '24	Sale	4.64	450	2,088	72,318	Apr 01 09:28 PM
Segal Lloyd Mitchell	PRESIDENT AND CEO	Mar 27 '24	Sale	4.63	2,650	12,270	83,866	Mar 27 06:54 PM
Forte Steve	EVP, CHIEF FINANCIAL OFFICER	Mar 27 '24	Sale	4.62	825	3,812	42,212	Mar 27 06:59 PM
Koehler Maria	EVP, CHIEF MEDICAL OFFICER	Mar 27 '24	Sale	4.62	500	2,310	232,209	Mar 27 06:56 PM
Zinda Michael	EVP, CHIEF SCIENTIFIC OFFICER	Mar 27 '24	Sale	4.62	450	2,079	72,768	Mar 27 06:57 PM
Segal Lloyd Mitchell	PRESIDENT AND CEO	Mar 26 '24	Sale	4.64	2,650	12,296	86,516	Mar 27 06:54 PM
Forte Steve	EVP, CHIEF FINANCIAL OFFICER	Mar 26 '24	Sale	4.60	825	3,795	43,037	Mar 27 06:59 PM
Koehler Maria	EVP, CHIEF MEDICAL OFFICER	Mar 26 '24	Sale	4.60	500	2,300	232,709	Mar 27 06:56 PM
Zinda Michael	EVP, CHIEF SCIENTIFIC OFFICER	Mar 26 '24	Sale	4.61	450	2,074	73,218	Mar 27 06:57 PM
Segal Lloyd Mitchell	PRESIDENT AND CEO	Mar 25 '24	Sale	4.79	2,650	12,694	89,166	Mar 27 06:54 PM
Forte Steve	EVP, CHIEF FINANCIAL OFFICER	Mar 25 '24	Sale	4.79	825	3,952	43,862	Mar 27 06:59 PM
Koehler Maria	EVP, CHIEF MEDICAL OFFICER	Mar 25 '24	Sale	4.78	500	2,390	233,209	Mar 27 06:56 PM
Zinda Michael	EVP, CHIEF SCIENTIFIC OFFICER	Mar 25 '24	Sale	4.78	450	2,151	73,668	Mar 27 06:57 PM
Koehler Maria	EVP, Chief Medical Officer	Dec 11 '23	Option Exercise	2.26	43,746	98,755	219,709	Dec 12 04:19 PM
BVF PARTNERS L P/IL	10% Owner	Nov 16 '23	Buy	5.38	295,745	1,592,202	5,309,432	Nov 17 04:54 PM
BVF PARTNERS L P/IL	10% Owner	Nov 15 '23	Buy	5.00	931,556	4,657,687	5,155,739	Nov 17 04:54 PM
BVF PARTNERS L P/IL	10% Owner	Nov 02 '23	Buy	3.60	783,709	2,821,352	4,662,402	Nov 03 05:37 PM
Zinda Michael	EVP, Chief Scientific Officer	Jun 07 '23	Sale	12.03	6,404	77,040	62,987	Jun 09 04:25 PM
Zinda Michael	EVP, Chief Scientific Officer	Jun 06 '23	Sale	12.04	1,200	14,448	69,391	Jun 07 04:55 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

TSBX

Turnstone Biologics Corp

RPTX

Repare Therapeutics Inc

Upgrade your FINVIZ experience